InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

- Current share price for MYX : $2.690

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$220 Becoming a substantial holder 9 Mar 2017 3:00PM $1.310 $2.690 risen by 105.34%
$220 Mayne Pharma appoints new Group CFO and Company Secretary 9 Mar 2017 9:11AM $1.335 $2.690 risen by 101.50%
$220 Mayne Pharma acquires rights to generic Duragesic in the US 9 Mar 2017 8:57AM $1.335 $2.690 risen by 101.50%
$220 Change of Director's Interest Notice 8 Mar 2017 12:44AM $1.360 $2.690 risen by 97.79%
$220 Appendix 3B 6 Mar 2017 11:33AM $1.420 $2.690 risen by 89.44%
$220 License and supply agreement for generic Nuvaring in the US 28 Feb 2017 8:20AM $1.520 $2.690 risen by 76.97%
$220 2017 Half Year Investor Presentation 24 Feb 2017 8:12AM $1.500 $2.690 risen by 79.33%
$220 2017 Half Year Media Release 24 Feb 2017 8:12AM $1.500 $2.690 risen by 79.33%
$220 Half Yearly Report and Accounts 24 Feb 2017 8:11AM $1.500 $2.690 risen by 79.33%
$220 Appendix 3B 20 Feb 2017 10:46AM $1.395 $2.690 risen by 92.83%
$220 Mayne Pharma launches Butalbital / APAP tablets in the US 16 Feb 2017 9:13AM $1.410 $2.690 risen by 90.78%
$220 Mayne Pharma announces leadership changes 16 Jan 2017 8:29AM $1.255 $2.690 risen by 114.34%
$220 Mayne Pharma launches Amiodarone 100mg tablets 13 Jan 2017 8:29AM $1.275 $2.690 risen by 110.98%
$220 Appendix 3B 12 Jan 2017 4:28PM $1.275 $2.690 risen by 110.98%
$220 Change of Director's Interest Notice 11 Jan 2017 10:58AM $1.353 $2.690 risen by 98.89%
$220 Mayne Pharma launches Fabior and Sorilux in the US 11 Jan 2017 8:27AM $1.320 $2.690 risen by 103.79%
$220 Appendix 3B 28 Dec 2016 12:56AM $1.390 $2.690 risen by 93.53%
$220 Change of Director's Interest Notice 28 Dec 2016 12:54AM $1.390 $2.690 risen by 93.53%
$220 Change of Director's Interest Notice (x4) 21 Dec 2016 4:46PM $1.365 $2.690 risen by 97.07%
$220 Appendix 3B 21 Dec 2016 4:44PM $1.365 $2.690 risen by 97.07%
$220 Change in substantial holding from CBA 21 Dec 2016 12:16AM $1.340 $2.690 risen by 100.75%
$220 Change of Director's Interest Notices (x2) 19 Dec 2016 9:16AM $1.300 $2.690 risen by 106.92%
$220 Update on Status of DOJ Investigation 16 Dec 2016 10:46AM $1.100 $2.690 risen by 144.55%
$220 Change in substantial holding from CBA 13 Dec 2016 4:28PM $1.453 $2.690 risen by 85.20%
$220 Appendix 3B 13 Dec 2016 10:52AM $1.453 $2.690 risen by 85.20%

726 - 750 of 906 results

Page 30 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.